1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,000 | 12,300 | 18.10. | |
| 11,800 | 12,500 | 17.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09. | MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board | 2 | Investing.com | ||
| 29.09. | MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors | 10 | GlobeNewswire (USA) | ||
| 25.09. | MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA | 2 | GlobeNewswire (USA) | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.09. | MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development | 1 | GlobeNewswire (USA) | ||
| 15.08. | MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results | 3 | Investing.com | ||
| 14.08. | MiNK Therapeutics GAAP EPS of -$1.06 misses by $0.51 | 4 | Seeking Alpha | ||
| 14.08. | MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | 147 | GlobeNewswire (Europe) | Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant... ► Artikel lesen | |
| 14.08. | MiNK Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | MiNK Therapeutics: H.C. Wainwright stuft Aktie nach Kursrallye auf "Neutral" herab | 17 | Investing.com Deutsch | ||
| 15.07. | MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright | 2 | Investing.com | ||
| 15.07. | Mink Therapeutics stock tumbles on $50 million stock offering | 5 | Investing.com | ||
| 15.07. | MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy | 1 | GlobeNewswire (USA) | ||
| 15.07. | Nach Kursrallye von über 460 %: MiNK Therapeutics kündigt Kapitalerhöhung über 50 Mio. US-Dollar an | 5 | Investing.com Deutsch | ||
| 14.07. | William Blair stuft MiNK-Therapeutics-Aktie nach 700-%-Rallye herab | 9 | Investing.com Deutsch | ||
| 14.07. | William Blair downgrades MiNK Therapeutics stock to Market Perform after 700% surge | 3 | Investing.com | ||
| 14.07. | MiNK Therapeutics stock maintains Buy rating at H.C. Wainwright after case study publication | 1 | Investing.com | ||
| 14.07. | MiNK Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 14.07. | MiNK Therapeutics stock falls after William Blair downgrade | 4 | Investing.com | ||
| 14.07. | XFRA 6Q40: WIEDERAUFNAHME/RESUMPTION | 331 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 41,600 | -0,48 % | EQS-News: BB BIOTECH AG: BB Biotech wird in den SPI ESG Index aufgenommen | EQS-News: BB BIOTECH AG
/ Schlagwort(e): ESG
BB Biotech wird in den SPI ESG Index aufgenommen
22.09.2025 / 07:00 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,600 | -0,47 % | Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have? | ||
| NOVOCURE | 11,835 | +0,25 % | Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress | Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,632 | -1,21 % | Oxford Nanopore Tech - Upcoming Investor Conferences and Events | ||
| MEREO BIOPHARMA | 1,720 | -2,55 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | |
| BIOLINERX | 3,130 | +2,79 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ASSERTIO | 0,801 | -2,44 % | Assertio Holdings, Inc.: Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN (clobazam) Oral Film, CIV | New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsyStudy addresses lack of awareness... ► Artikel lesen | |
| ROIVANT SCIENCES | 14,615 | -1,15 % | Roivant Sciences auf Rekordhoch: Aktie klettert auf 16,8 USD | ||
| APPLIED THERAPEUTICS | 1,052 | -3,71 % | Applied Therapeutics Provides Update Following Meeting with FDA | NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the Company), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for... ► Artikel lesen | |
| AKERO THERAPEUTICS | 46,110 | -0,04 % | Novo Nordisk's Akero Therapeutics Buy Targets Eli Lilly's Lead | ||
| ARVINAS | 9,520 | -1,60 % | Forecasting The Future: 7 Analyst Projections For Arvinas | ||
| REVOLUTION MEDICINES | 46,600 | +6,88 % | Stocks making the biggest moves midday: Oracle, AST SpaceMobile, Revolution Medicines and more | ||
| JANUX THERAPEUTICS | 26,760 | -1,65 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| WEREWOLF THERAPEUTICS | 1,590 | -4,22 % | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer | Fast Track Designation underscores the promise of Werewolf's INDUKINE platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq:... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 15,260 | +1,67 % | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen |
Das Unternehmen MINK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,80 % bei einem Aktienkurs von 11,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.